BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 17544845)

  • 21. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
    Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
    BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
    Sartor O; Hoskin P; Coleman RE; Nilsson S; Vogelzang NJ; Petrenciuc O; Staudacher K; Thuresson M; Parker C
    Prostate; 2016 Jul; 76(10):905-16. PubMed ID: 27004570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.
    Smith MR; Saad F; Coleman R; Shore N; Fizazi K; Tombal B; Miller K; Sieber P; Karsh L; Damião R; Tammela TL; Egerdie B; Van Poppel H; Chin J; Morote J; Gómez-Veiga F; Borkowski T; Ye Z; Kupic A; Dansey R; Goessl C
    Lancet; 2012 Jan; 379(9810):39-46. PubMed ID: 22093187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials.
    Rugo HS; Van Poznak CH; Neven P; Danielewicz I; Lee SC; Campone M; Chik JYK; Vega Alonso E; Naume B; Brain E; Siegel JM; Li R; Uema D; Wagner VJ; Coleman RE
    Breast Cancer Res Treat; 2024 Apr; 204(2):249-259. PubMed ID: 38123789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.
    Nilsson S; Strang P; Aksnes AK; Franzèn L; Olivier P; Pecking A; Staffurth J; Vasanthan S; Andersson C; Bruland ØS
    Eur J Cancer; 2012 Mar; 48(5):678-86. PubMed ID: 22341993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects.
    Lewis B; Chalhoub E; Chalouhy C; Sartor O
    Oncology (Williston Park); 2015 Jul; 29(7):483-8. PubMed ID: 26178336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review.
    Croke J; Leung E; Segal R; Malone S
    BMJ Case Rep; 2012 Nov; 2012():. PubMed ID: 23125297
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Ahmadzadehfar H; Azgomi K; Hauser S; Wei X; Yordanova A; Gaertner FC; Kürpig S; Strunk H; Essler M
    J Nucl Med; 2017 Mar; 58(3):438-444. PubMed ID: 27660148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.
    Nilsson S; Larsen RH; Fosså SD; Balteskard L; Borch KW; Westlin JE; Salberg G; Bruland OS
    Clin Cancer Res; 2005 Jun; 11(12):4451-9. PubMed ID: 15958630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of pre-treatment variables on the completion of
    Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
    Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone-targeting radiopharmaceuticals including radium-223.
    Brady D; Parker CC; O'Sullivan JM
    Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing Radiographic Response to
    Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
    J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.
    van der Doelen MJ; Stockhaus A; Ma Y; Mehra N; Yachnin J; Gerritsen WR; Nilsson S; van Oort IM; Ullén A
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3325-3334. PubMed ID: 33686456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
    Sartor O; Coleman RE; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Vogelzang NJ; Bruland Ø; Kobina S; Wilhelm S; Xu L; Shan M; Kattan MW; Parker C
    Ann Oncol; 2017 May; 28(5):1090-1097. PubMed ID: 28453701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer.
    Parikh S; Murray L; Kenning L; Bottomley D; Din O; Dixit S; Ferguson C; Handforth C; Joseph L; Mokhtar D; White L; Wright G; Henry AM
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):548-555. PubMed ID: 29934104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
    J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
    Yamamoto Y; Okuda Y; Kanaki T; Tanaka R; Nagahara A; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
    Int J Clin Oncol; 2021 Jan; 26(1):192-198. PubMed ID: 32875513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radium Ra 223 dichloride in castration-resistant prostate cancer.
    Joung JY; Ha YS; Kim IY
    Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Radium-223 treatment of bone metastases from castration-resistant prostate cancer].
    Mortensen J; Højgaard L
    Ugeskr Laeger; 2014 Jul; 176(30):1399-402. PubMed ID: 25292232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.